Omnicell’s (OMCL) Buy Rating Reiterated at Benchmark

Benchmark restated their buy rating on shares of Omnicell (NASDAQ:OMCL) in a report published on Tuesday,Benzinga reports. They currently have a $62.00 price target on the stock.

OMCL has been the subject of several other research reports. JPMorgan Chase & Co. boosted their price objective on shares of Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a research report on Thursday, November 21st. Wells Fargo & Company reduced their price target on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. StockNews.com lowered Omnicell from a “buy” rating to a “hold” rating in a report on Tuesday, December 10th. Barclays boosted their target price on Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Finally, Bank of America dropped their price target on Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research note on Monday, January 6th. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $52.33.

Omnicell Trading Down 11.2 %

Omnicell stock opened at $39.43 on Tuesday. The company has a fifty day simple moving average of $44.52 and a 200-day simple moving average of $43.23. The stock has a market cap of $1.83 billion, a P/E ratio of -101.10, a price-to-earnings-growth ratio of 30.78 and a beta of 0.78. Omnicell has a 12-month low of $25.12 and a 12-month high of $55.74.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a positive return on equity of 2.55% and a negative net margin of 1.66%. As a group, sell-side analysts forecast that Omnicell will post 0.94 earnings per share for the current fiscal year.

Insider Buying and Selling at Omnicell

In other news, Director Mark W. Parrish sold 12,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total value of $567,600.00. Following the transaction, the director now owns 58,427 shares of the company’s stock, valued at approximately $2,763,597.10. The trade was a 17.04 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 2.64% of the stock is owned by company insiders.

Hedge Funds Weigh In On Omnicell

A number of hedge funds and other institutional investors have recently bought and sold shares of OMCL. Proficio Capital Partners LLC purchased a new position in Omnicell during the 4th quarter worth $1,542,000. M&T Bank Corp raised its holdings in Omnicell by 51.2% during the fourth quarter. M&T Bank Corp now owns 25,934 shares of the company’s stock worth $1,155,000 after purchasing an additional 8,786 shares in the last quarter. Victory Capital Management Inc. raised its holdings in Omnicell by 32.9% during the fourth quarter. Victory Capital Management Inc. now owns 1,526,309 shares of the company’s stock worth $67,951,000 after purchasing an additional 377,883 shares in the last quarter. Keybank National Association OH lifted its position in Omnicell by 32.1% in the fourth quarter. Keybank National Association OH now owns 8,902 shares of the company’s stock valued at $396,000 after purchasing an additional 2,161 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in Omnicell by 3.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 616,153 shares of the company’s stock worth $27,431,000 after purchasing an additional 21,157 shares during the period. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.